Lifeboat Foundation

Osteoarthritis affects as many as 30 million Americans, but treatment has traditionally been limited to managing symptoms with pain relievers and lifestyle changes. In a new Nature study, YSM researchers identify a new therapeutic target that could help slow and reverse joint damage from osteoarthritis.

Yale researchers have identified a drug target that may alleviate joint degeneration associated with osteoarthritis, a debilitating condition that afflicts as many as 30 million people in the United States alone, they report Jan. 3 in the journal Nature.

Pain relievers and lifestyle changes, such as exercise and reduced excess weight, have long been the therapies most commonly used to treat the joint stiffness and pain caused by the degenerative disease, but there is a pressing need for therapies that can prevent joint breakdown that occurs in osteoarthritis.

Continue reading “Epilepsy drug shows promise in slowing joint degeneration in osteoarthritis” »

Australian researchers have successfully trialed a novel experiment to address offensive and rude comments in operating theaters by placing “eye” signage in surgical rooms.

The eye images, attached to the walls of an Adelaide orthopaedic hospital’s operating theater without any explanation, had the desired effect of markedly reducing poor behavior among surgical teams.

Lead researcher University of South Australia Professor Cheri Ostroff attributed the result to a perception of being “watched,” even though the eyes were not real.

A s the world moves away from gas towards electricity as a greener power source, the to-do list goes beyond cars. The vast global manufacturing network that makes everything from our batteries to our fertilizers needs to flip the switch, too.

A study from UChicago chemists found a way to use electricity to boost a type of chemical reaction often used in synthesizing new candidates for pharmaceutical drugs.

Published Jan. 2 in Nature Catalysis, the research is an advance in the field of electrochemistry and shows a path forward to designing and controlling reactions—and making them more sustainable.

This is a good thing to know.

Microbes living in our guts ooze a substance that could help protect us against excessive weight gain, according to observations in mice.

The bacteria-derived compound may explain why early exposure to antibiotics can play a role in childhood obesity, a condition which is rising globally.

Continue reading “Chemical Produced by Gut Microbes Seems to Prevent Obesity in Mice” »

Scientists have developed a new class of polymers that may kill bacteria without causing antibiotic resistance.

Antibiotic-resistant microorganisms are one of the most serious risks to global public health.

According to the Centers for Disease Control and Prevention, antibiotic-resistant bacteria cause as many as 2.8 million infections in the United States each year.

LONDON, Jan 4 (Reuters Breakingviews) — Yemen’s Houthis are stirring up the Red Sea and shipping company investors. Denmark’s Maersk (MAERSKb. CO) and Germany’s Hapag-Lloyd (HLAG.DE), for example, have gained some $18 billion in market value since mid-December, as militant attacks shut the Suez Canal, causing freight rates to double. Yet hopes for a lasting boost may be disappointed.

Maersk this week decided to shun the Suez Canal indefinitely, where 12% of global trade passes through. That’s after one of the $35 billion group’s vessels narrowly escaped a hijacking thanks to U.S. helicopters, in turn prompting Iran, which backs the Houthi rebels, to send in a warship. As a result, shipping groups are now re-routing major trade lanes including the Asia to Europe traffic around Africa’s Cape of Good Hope, which adds at least 10 days of travel time.

The extra time and riskiness of the journey has caused freight rates to soar. Asia to Europe prices, for example, have nearly doubled since mid-December to more than $4,000 per forty-foot equivalent unit (FEU), Freightos data showed as of Jan. 3. While that’s still a far cry from the more than 10-fold increase during the pandemic, the result should be a windfall for shipping groups.

In a recent study published in Molecular Psychiatry, researchers explored the effects of a small humanin-like peptide 2 (SHLP2) variant on mitochondrial function.

Mitochondria are implicated in Parkinson’s disease (PD) pathogenesis. Mitochondrial-derived peptides (MDPs) are microproteins encoded from small open reading frames (sORFs) in the mitochondrial DNA (mtDNA). SHLP2 is an MDP with an essential role in multiple cellular processes, and it improves mitochondrial metabolism by increasing biogenesis and respiration and reducing oxidation.

Recent studies link mitochondrial single nucleotide polymorphisms (mtSNPs) within coding regions of MDPs to age-related deficits. For instance, m.2706 A G, an mtSNP in humanin, predicts reduced circulating levels of humanin and worse cognitive decline. Moreover, another mtSNP, m.2158 T C, is associated with reduced PD risk, albeit the underlying mechanisms are unknown.

A study of around 500,000 medical records suggested that severe viral infections like encephalitis and pneumonia increase the risk of neurodegenerative diseases like Parkinson’s and Alzheimer’s.

Recent studies by Zampaloni et al. and Pahil et al. published in the journal Nature describe a novel method of inhibiting the growth of Gram-negative bacteria such as Acinetobacter using antibiotics consisting of macrocyclic peptides that target the bacterial protein bridge machinery that transports lipopolysaccharides from the cytoplasm to the outer membrane.

The amphipathic lipopolysaccharides in the outer leaflet of the asymmetric outer membrane bilayer of Gram-negative bacteria block antibiotic entry, making the treatment of bacterial infections involving Gram-negative bacteria difficult. Furthermore, the development of antibiotic resistance in bacteria, especially Gram-negative bacteria such as Acinetobacter baumannii, is a rapidly increasing global health concern since antibiotic-resistant bacterial infections are becoming increasingly common among hospitalized and critically ill patients.

The lipopolysaccharide is synthesized inside the bacterial cell in the inner membrane, transported across the cell membrane, and assembled in the outer leaflet. The transportation of lipopolysaccharides occurs with the help of LptB₂FGC, a subcomplex in the inner membrane that enlists adenosine triphosphate (ATP) hydrolysis and a protein bridge to extract lipopolysaccharides from the inner membrane and transport it to the outer membrane. Targeting this transportation complex could effectively inhibit the lipopolysaccharide biosynthesis, making the Gram-negative bacteria susceptible to antibacterial activity.